Oncologists must confront end-of-life issues on a nearly daily basis. Our approach to the potential death of a patient may change over time, however, depending on the patients' diagnosis and stage, where those patients are in their treatment plan, and, of course, what the patients' wishes are. When feasible, our primary goal is to prevent death from cancer, and when we cannot achieve that, we try to delay death as long as we can. When dying seems inevitable, we do our best to make it as comfortable as possible.
A budget proposed by President Donald Trump would set NIH and biomedical research back 15 years, said former Vice President Joe Biden, addressing members of the American Association for Cancer Research on April 3.
The FDA Oncologic Drugs Advisory Committee March 29 unanimously recommended approval of a lymphoma treatment, to be administered via subcutaneous injection.
It's fair to say that eight years ago, when the Obama administration infused the economy with $800 billion in stimulus funding, policymakers likely did not expect the health information technology industry to evolve into fiefdoms guarded by legions of lawyers and walls of proprietary code.
FDA granted an accelerated approval to Bavencio (avelumab) for the treatment of patients 12 years and older with metastatic Merkel cell carcinoma.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
In a simple definition, cancer is a disease of the cells, which is caused by gene mutations. For a proportion of patients, including women with hormone receptor positive breast cancer, gene expression profiling has a substantial impact on treatment decision-making by determining which patients might—or might not—respond to particular treatment options.
Researchers led by St. Jude Children's Research Hospital scientists have worked out how a crucial cancer-related protein, a "histone writer" called Ezh2, plays a role in suppressing as well as driving the most aggressive form of the brain tumor medulloblastoma.
OncoGenex Pharmaceuticals Inc. said apatorsen results from two randomized phase II clinical trials were presented at the American Society of Clinical Oncology 2017 Genitourinary Cancers Symposium.
A new study offers a treatment option for patients with recurrent lung cancer, who historically have been considered ineligible for curative treatment.
